🇺🇸 FDA
Patent

US 10737995

Nuclear receptor modulators and their use for the treatment and prevention of cancer

granted A61KA61K31/12A61K31/275

Quick answer

US patent 10737995 (Nuclear receptor modulators and their use for the treatment and prevention of cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/12, A61K31/275, A61K45/06, A61P